21 CFR 820.198: Complaint files

Required manufacturers to maintain complaint files and procedures through a designated unit to receive, evaluate, and investigate complaints, assess reportability as adverse events, and keep detailed investigation records accessible to the manufacturing site and the U.S.

Part 820, Quality System Regulation · Subpart M, Records

Most device 483s cite the Quality System Regulation in force before February 2, 2026, when the QMSR replaced it. Those sections are marked Former.

How FDA words it

The opening lines investigators use most when they cite 820.198, from the 483s we hold.

Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.Most used
Complaints involving the possible failure of a device to meet any of its specifications were not investigated where necessary.820.198(c)
Complaint files are not adequately maintained.820.198(a)

Cited over time

483s citing 820.198, by year

Most citations in 2019. Bars are relative to the busiest year. *2026 to date.

Years shown: 2017 to 2026. The busiest year was 2019.

Recent 483s citing 820.198

See all 483s citing 820.198

The regulation text

§ 820.198 Complaint files. As published before it was replaced.

(a)Each manufacturer shall maintain complaint files. Each manufacturer shall establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit. Such procedures shall ensure that:

(1)All complaints are processed in a uniform and timely manner;

(2)Oral complaints are documented upon receipt; and

(3)Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting.

(b)Each manufacturer shall review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer shall maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate.

(c)Any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated, and investigated, unless such investigation has already been performed for a similar complaint and another investigation is not necessary.

(d)Any complaint that represents an event which must be reported to FDA under part 803 of this chapter shall be promptly reviewed, evaluated, and investigated by a designated individual(s) and shall be maintained in a separate portion of the complaint files or otherwise clearly identified. In addition to the information required by § 820.198(e), records of investigation under this paragraph shall include a determination of:

(1)Whether the device failed to meet specifications;

(2)Whether the device was being used for treatment or diagnosis; and

(3)The relationship, if any, of the device to the reported incident or adverse event.

(e)When an investigation is made under this section, a record of the investigation shall be maintained by the formally designated unit identified in paragraph (a) of this section. The record of investigation shall include:

(1)The name of the device;

(2)The date the complaint was received;

(3)Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used;

(4)The name, address, and phone number of the complainant;

(5)The nature and details of the complaint;

(6)The dates and results of the investigation;

(7)Any corrective action taken; and

(8)Any reply to the complainant.

(f)When the manufacturer's formally designated complaint unit is located at a site separate from the manufacturing establishment, the investigated complaint(s) and the record(s) of investigation shall be reasonably accessible to the manufacturing establishment.

(g)If a manufacturer's formally designated complaint unit is located outside of the United States, records required by this section shall be reasonably accessible in the United States at either:

(1)A location in the United States where the manufacturer's records are regularly kept; or

(2)The location of the initial distributor.

[61 FR 52654, Oct. 7, 1996, as amended at 69 FR 11313, Mar. 10, 2004; 71 FR 16228, Mar. 31, 2006; 78 FR 58822, Sept. 24, 2013]

Questions

What does 21 CFR 820.198 require?

Required manufacturers to maintain complaint files and procedures through a designated unit to receive, evaluate, and investigate complaints, assess reportability as adverse events, and keep detailed investigation records accessible to the manufacturing site and the U.S.

How do FDA investigators word a 820.198 observation?

The most common opening is: “Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.”

Which sections are cited alongside 820.198?

In the same 483s, investigators most often also cite 820.100 (Corrective and preventive action), 820.30 (Design controls), 820.50 (Purchasing controls), 820.90 (Nonconforming product).